Bayer to Present Data on Investigational Pulmonary Hypertension Compound at CHEST 2012

WAYNE, N.J., Oct. 17, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.  Data from two pivotal, Phase III trials researching riociguat in patients with for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) will be presented as late-breaking abstracts in oral presentation sessions.

"At Bayer, we are dedicated to researching new treatment options for people living with devastating diseases, like pulmonary hypertension," said Pamela A. Cyrus, M.D., Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  "We are pleased to present top-line results of riociguat and its potential as a treatment option for PAH and CTEPH."

The studies to be presented are:

Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double-blind, placebo-controlled study (CHEST-1)
Abstract 1462924; Late Breaking Abstract Session
October 23, 2012, 4:30 p.m. – 5:45 p.m., Convention Center,
Room C206
Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1)
Abstract 1462799 Late Breaking Abstract Session
October 23, 2012, 4:30 p.m. – 5:45 p.m., Convention Center,
Room C206
About Riociguat
Riociguat (BAY 63-2521), discovered and developed at the Bayer research laboratories, is an investigational oral soluble guanylate cyclase (sGC) stimulator.  It is currently being developed for its potential to treat patients with various types of PH.

Riociguat is an investigational agent and is not approved by the FDA, EMA or other health authorities.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SOURCE Bayer HealthCare

 
CONTACT: (Intended for U.S. media only): Marcy Funk, Communications, Bayer HealthCare, +1-973-305-5385, marcy.funk@bayer.com

Web Site: http://www.bayer.com


 
 

Posted: October 2012

View comments

Hide
(web4)